PHVS Pharvaris NV

Pharvaris to Participate in Upcoming September Investor Conferences

Pharvaris to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in the following three upcoming investor conferences in September:

Morgan Stanley 19th Annual Global Healthcare Conference

Format: Live Fireside Chat

Date/Time: Friday, September 10, 2021 at 5:00 PM CEST (11:00 a.m. EDT)

H.C. Wainwright 23rd Annual Global Investment Conference

Format: On Demand Presentation

Date/Time: Monday, September 13, 2021 at 1:00 PM CEST (7:00 a.m. EDT)

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Format: Live Presentation

Date/Time: Tuesday, September 21, 2021 at 3:05 PM CEST (9:05 a.m. EDT)

Live audio webcasts of these presentations will be available on the Investors section of the Pharvaris website at: . A replay will be available on Pharvaris’ website for 30 days after each respective date.

About Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit .

For more information:

Pharvaris

Maryann Cimino

Director of Corporate Relations



Investor Contact

Sarah McCabe

Stern Investor Relations, Inc.



Media Contact

Maggie Beller

Russo Partners, LLC





EN
03/09/2021

Underlying

PHVSPharvaris NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharvaris NV

Guy Sips ... (+6)
  • Guy Sips
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
HEIA HEINEKEN NV
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
RAND RANDSTAD NV
LOTB LOTUS BAKERIES NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ALFEN ALFEN NV
PHVS PHARVARIS NV
02/11/26 February 11, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
PHVS PHARVARIS NV

Pharvaris To present clinical data at the AAAAI 2026

Pharvaris will present multiple datasets at AAAAI 2026, including topline RAPIDe-3 results, final CHAPTER-1 data, supporting evidence for the extended-release formulation, AMRA endpoint validation, and results from a new kinin biomarker assay. We look forward to the prophylactic phase 3 (CHAPTER-3) readout in 3Q26 and reiterate our Buy and $ 36 TP.

02/11/26 February 11, 2026 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for p...

February 10, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
PHVS PHARVARIS NV

Pharvaris Business update narrows topline prophylactic phase 3 data to...

Pharvaris provided a business update, which comes with narrowed guidance for the topline data from the phase 3 (CHAPTER-3) trial of deucrictibant in HAE prophylaxis, now expected in 3Q26 (previously 2H26). We're confident going into this readout, which we believe has a high probability of success based on the strong efficacy shown in phase 2. With the NDA filing in the on-demand setting on track for 1H26, and another phase 3 ongoing in AAE-C1INH, the product is set to address the broadest group ...

01/13/26 January 13, 2026 1 EN
Jacob Mekhael ... (+4)
  • Jacob Mekhael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Wim Hoste
GBLB GROUPE BRUXELLES LAMBERT SA
UCB UCB S.A.
ONTEX ONTEX GROUP N.V.
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
PHVS PHARVARIS NV
MDXH MDXHEALTH
01/13/26 January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch